No profile data available.
Harmony Biosciences Holdings, Inc. (HRMY) is a healthcare company in the brain and nerve treatment drugs industry, based in Plymouth Meeting, United States, with about 293 full-time employees.
It reported revenue of $868.45 million for fiscal year 2025, up 21.5% from fiscal year 2024, and net income of $158.69 million. Its market capitalization was $2.35 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.
Harmony Biosciences reported $868.45 million in revenue for fiscal year 2025, up 21.5% from $714.73 million in fiscal year 2024.
$2.35 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (brain and nerve treatment drugs) include Denali Therapeutics Inc. (DNLI), Dyne Therapeutics, Inc. (DYN), Supernus Pharmaceuticals, Inc. (SUPN), Sarepta Therapeutics, Inc. (SRPT).